Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for screening anthracycline cardiotoxicity genes through mRNA expression profiles and competitive endogenesis RNA expression profiles jointly

A technology of cardiotoxicity and differentially expressed genes, applied in bioinformatics, special data processing applications, instruments, etc., can solve problems such as unsatisfactory curative effect and difficult clinical treatment

Active Publication Date: 2016-12-07
JINZHOU MEDICAL UNIV
View PDF4 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The present invention aims to solve the technical problem that the non-invasive monitoring of the cardiotoxicity of anthracyclines can only be detected at a relatively late stage in the prior art, resulting in difficulties in clinical treatment and unsatisfactory curative effect, and provides a method using mRNA expression profiles and competitive A combined screening method for anthracycline cardiotoxicity genes by endogenous RNA expression profiling

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for screening anthracycline cardiotoxicity genes through mRNA expression profiles and competitive endogenesis RNA expression profiles jointly

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The present invention will be described in detail below in conjunction with the accompanying drawings.

[0023] The method for jointly screening anthracycline cardiotoxicity genes by using mRNA expression profile and competitive endogenous RNA expression profile of the present invention, taking the use of mRNA expression profile and miRNA expression profile as an example, includes the following steps:

[0024] 1. Collection of peripheral blood and acquisition of mRNA gene expression profile and miRNA gene expression profile

[0025] 1. Object

[0026] From January 2016 to December 2016, 6 serum samples from breast cancer patients without cardiotoxicity before chemotherapy and 6 patients with cardiotoxicity after anthracyclines were collected in the Oncology Department of a hospital, and 10 healthy volunteers were collected during the same period Those who served as controls (the total RNA samples extracted from 3 people in each group were used for sequencing to detect ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for screening anthracycline cardiotoxicity genes through mRNA expression profiles and competitive endogenesis RNA expression profiles jointly. The method includes the steps that expression values of a large quantity of genes are detected through mRNA and competitive endogenesis RNA expression profile chips, and the correlations of all the genes are ordered; the obtained mRNA feature genes and the obtained competitive endogenesis RNA feature genes are combined; a gene pool is subjected to further gene selection with a genetic algorithm; differential expression genes are selected by comparing the data between different samples of mRNA and competitive endogenesis RNA joint expression profiles of breast cancer patients, breast cancer AIC patients and able-bodied persons; the differential expression genes are predicted, and the genes with the scores larger than 140 and free energy smaller than 20 are selected as reliable target genes; genes with obvious differences are selected from the target genes, and constructed breast-cancer anthracycline cardiotoxicity attacking target genes are verified through the residual RNA. By means of the method, more reliable potential gene markers related to anthracycline cardiotoxicity can be selected as a candidate.

Description

technical field [0001] The invention relates to the technical field of gene expression profile analysis, in particular to a method for jointly screening anthracycline cardiotoxicity genes by using mRNA expression profile and competitive endogenous RNA expression profile. Background technique [0002] About 81.4% of all invasive breast cancer patients in China received adjuvant chemotherapy and had a high tumor cure rate. However, long-term survivors of breast cancer patients currently have problems: the mortality rate due to cardiac causes is 8.2 times higher; long-term survivors have a 15-fold higher risk of heart failure and a 10-fold higher risk of cardiovascular disease. According to the 2015 NCCN guidelines for breast cancer, the preferred adjuvant chemotherapy regimen is AC×4→T(P)×4 (pirarubicin / cyclophosphamide-paclitaxel). Anthracyclines have broad antitumor spectrum and strong antitumor activity. Received high evaluation in chemotherapy. The most prominent chemoth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G06F19/20
CPCG16B25/00
Inventor 王亚帝任立群李敏陈素贤何东宁
Owner JINZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products